Raymond James set a C$13.50 price target on Vitalhub (TSE:VHI – Free Report) in a research note released on Thursday,BayStreet.CA reports. The brokerage currently has an outperform rating on the stock.
VHI has been the subject of several other research reports. Canaccord Genuity Group boosted their price objective on shares of Vitalhub from C$12.00 to C$12.50 and gave the stock a “buy” rating in a research report on Thursday, January 16th. Scotiabank set a C$14.00 price target on shares of Vitalhub and gave the stock an “outperform” rating in a research note on Thursday, January 30th. Five equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of C$11.92.
View Our Latest Analysis on VHI
Vitalhub Stock Performance
About Vitalhub
Vitalhub Corp., together with its subsidiaries, provides technology solutions for health and human service providers in Canada, the United States, the United Kingdom, Australia, Western Asia, and internationally. Its solutions include electronic healthcare record, case management, care coordination and optimization, and patient flow, engagement, and operational visibility solutions.
Featured Stories
- Five stocks we like better than Vitalhub
- What Are Dividend Challengers?
- Penny Stock SurgePays Rises 70%: 1 Reason to Buy, 5 to SellĀ
- Financial Services Stocks Investing
- Top 3 Beverage Stocks Pouring Out Profits
- Uptrend Stocks Explained: Learn How to Trade Using Uptrends
- CarMax and Carvana: Steering the Used Car Market
Receive News & Ratings for Vitalhub Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vitalhub and related companies with MarketBeat.com's FREE daily email newsletter.